The immunodiagnostics market size was valued at USD 22.24 billion in 2024 and is expected to reach USD 38.40 billion by 2032, growing at a CAGR of 7.09% over 2025-2032.
The immunodiagnostics market is experiencing high growth due to the rise in prevalence of cancer, infectious diseases, and autoimmune diseases, increased awareness, and the need for early detection. For instance, breast cancer is still the most diagnosed cancer in women globally, and over 2.3 million people develop it yearly (American Cancer Society, 2024).
Likewise, global rates of HIV are still significant, with more than 1.2 million people in the U.S being HIV positive, emphasizing the necessity for ongoing diagnostic testing (CDC HIV Surveillance, 2024). Market participants on the supply side are exercising tactical acquisitions, enhanced product offerings, and increased production capacity to meet demand. PerkinElmer acquired Immunodiagnostic Systems in 2023 to expand its specialty diagnostics portfolio, and Freenome bought Oncimmune Ltd. in 2023 to augment its immune profiling portfolio for early cancer detection.
For instance, in February 2025, Korea’s National Microbiome Framework Facility announced support for the development of AI-powered immunodiagnostics through academic–industry cooperation, showcasing cross-sector partnerships in R&D and commercialization.
R&D spending and government funding are also driving the market. The NIH awarded USD 4.2 billion on immunology and diagnostics in FY2023, and leading institutions, such as Johns Hopkins, are developing rapid diagnostic tests for infectious diseases that have real-time improved sensitivity. The development of new technologies, including photoelectrochemical immunosensors, nanoplasmonic biosensors, and AI-based analytical platforms, contributes to testing optimization and time-to-result decrease. Furthermore, regulatory agencies, including the FDA and EMA, have fast-tracked approvals for essential immunodiagnostics, especially post-COVID-19, making way in the market for new entrants and innovative products.
In October 2024, Auburn University's Dr. Pengyu Chen landed a multi-year extension award from the NIH to create nanotechnology-based diagnostics for infectious diseases, signaling an increase in federal funding for next-gen immunodiagnostics.
Market Dynamics:
Drivers:
Growing Disease Burden, Technological Advancements, and R&D Funding Are Driving the Immunodiagnostics Market Forward
Growth of the immunodiagnostics market is driven by the rising incidence of chronic and infectious diseases, increasing availability of funds for research, and the growth in funding for research. For instance, commercials diseases such as autoimmune diseases affect around 4% of the global population (WHO, 2024), while infections are also responsible for 1.3 million deaths per year, including tuberculosis with infections (WHO, 2024). This has continued to drive both public and private investments.
The EU4Health Programme was set up by the European Commission in 2024, offering more than €5.3 billion to support health innovations, including diagnostic capacity. On the innovation side, biotechnology players, such as Roche Diagnostics and BioMérieux, are incorporating multiplex assay technology as well as artificial intelligence into immunoassay platforms in order to enhance accuracy and decrease time-to-diagnosis. The U.S. FDA has also granted breakthrough device designations to multiple immunodiagnostic devices to expedite their regulatory approval. There are also skyrocketing numbers of academic/diagnostics firm partnerships (the University of Oxford is co-developing antibody-based rapid tests for emerging pathogens with Thermo Fisher). As global healthcare moves toward preventative health, the need for scalable, rapid, inexpensive diagnostics will only increase, thereby positioning immunodiagnostics as a cornerstone of modern medical diagnostics.
Restraints:
Regulatory Complexities, High Cost of Advanced Diagnostics, and Skilled Workforce Gaps That Challenge Market Expansion
The strict regulatory landscape is one of the main barriers. Immuno-diagnostic products need to satisfy multiple staged regulatory clearances from the likes of the FDA, EMA, and TGA, which tend to lengthen time-to-market. For instance, in the U.S., premarket approval (PMA) for Class III immunodiagnostic devices could require 180 days or longer, especially when novel biomarkers were involved. There is also the problem of very high costs of established immunoassay platforms (over USD 250,000 per unit), which limits their use in resource-limited environments and smaller diagnostic facilities. There is a lack of a trained workforce to perform and interpret high complexity immunoassays, which is still unmet in many areas, as evidenced by the 2023 report of the WHO that estimated the deficit of over 5 million clinical laboratory professionals internationally.
Supply chain weaknesses also bottleneck reagents and critical raw materials, especially in times of geopolitical disturbances. In addition, high-level quality control must be assured in multiplex or high-throughput systems with continuous technical and calibration support, which drives costly long-term maintenance expenses. These hindrances can impede the adoption of innovation and keep it from reaching widespread use, particularly in developing countries that have budget restrictions and/or infrastructure limitations.
By Product
The reagents & consumables market is projected to be the fastest-growing segment during the forecast period, as they are highly consumed in each testing cycle and are relatively inexpensive and easy to replace, in addition to the increasing number of tests performed in infectious diseases and oncology. High test volume in routine diagnostics and specialized immunoassays, and the availability of high-sensitivity reagents are major factors. Furthermore, the novelty in enzyme labeled reagents, nanoparticle-labeled antibodies, and lyophilized kits sections is improving the longevity and dependability of these consumables. Manufacturers are now scaling up production lines of reagents due to the increasing prevalence of diseases around the world, in decentralized and point-of-care conditions.
By Application
The oncology & endocrinology application field held the largest market share of 28.6% in 2024. The growth is on account of the increasing occurrence of cancer and hormonal diseases, including diabetes and thyroid malfunction. The growing importance of tumor marker testing and hormonal assay screening in early cancer diagnosis and endocrine dysfunction has broadened the horizon of immuno-diagnostic applications. Biological markers have also become popular in the clinic, catalyzed by the availability of panels of markers, such as CA-125 for ovarian cancer, and PSA for prostate cancer.
The infectious diseases application is expected to be the fastest-growing segment due to the rising incidence of viral infections, such as COVID-19, RSV, or monkeypox. The increasing pressure of AMR and the upsurge in the need for reliable and rapid pathogen detection have driven the development of more sophisticated immunodiagnostic kits. Businesses are also focusing on multiplex testing formats for the simultaneous detection of several pathogens, driving uptake in both developed and developing regions.
By End-user
The clinical laboratories end-user category is projected to witness the highest CAGR as a result of the progressive conversion of diagnostic testing from hospitals to specialized labs in an attempt to achieve better operational efficiency, reduced turnaround times, and low costs. The increase in outsourced diagnostic services and health system partnerships with big reference labs is driving testing volume. Along these lines, technological adoption, such as automation and LIMS (Laboratory Information Management Systems), is being used to streamline operations, further positioning clinical labs as the preferred environment for immunodiagnostic testing.
The immunodiagnostics market in North America, however, is estimated to be the largest in 2024 and also the fastest-growing region over the forecast period, owing to high healthcare expenditure, the presence of diagnostic majors, such as Abbott and Quest Diagnostics, and well-established infrastructure for laboratory and POC testing.
The U.S. immunodiagnostics market size was valued at USD 8.91 billion in 2024 and is expected to reach USD 13.67 billion by 2032, growing at a CAGR of 5.56% over 2025-2032. The U.S. is the largest nation attributed to a major share due to the large number of disease screening programs, such as cancer and infectious diseases. Across the U.S., the number of cancer screenings in 2024 reached more than 18 million (ACS), and immunodiagnostics play an important role in this workflow. Canada is also enhancing its diagnostics capacity through partnerships between the public and private sectors and by relying on AI-centered automation of labs. The fastest introduction of testing has been in Mexico, where the government has been pushing to decentralize the testing and get it out into rural areas.
Europe was the second largest market for the immunodiagnostics market owing to nationalized health programs, early disease detection programs and increasing research and development collaborations. Germany leads the regional market due to its strong diagnostic infrastructure and early launch of automated immunoassay systems. In 2024, over 125 million diagnostic tests are performed each year in clinical laboratories, with some of them being immunoassays. It is the fastest-growing country globally, driven by initiatives by the NHS to digitize diagnostic workflows and improve cancer screening penetration. France and Italy are also large contributors to immunodiagnostic R&D with vigorous academic-industry partnerships.
Asia Pacific is a growing region in the immunodiagnostics market, as it has a large patient base and increasing healthcare expenditure, and demand for high-quality diagnostic products. China is taking the lead, supported by government-funded healthcare reform and a large home-grown diagnostic manufacturing base. In 2024, China spent more than USD 10 billion on its national diagnostics expansion plan. India is the fastest-growing country, driven by programs such as Ayushman Bharat and a growing demand for low-cost, high-throughput testing for tuberculosis, hepatitis, and cancer. Japan and South Korea are also growing their clinical diagnostics offerings with AI and molecular testing combinations rolled out in urban health care facilities.
Leading immunodiagnostics companies operating in the market are Abbott, Roche Diagnostics, DiaSorin, Danaher Corporation, QIAGEN, bioMérieux, Thermo Fisher Scientific, Quest Diagnostics, Siemens Healthineers, and Becton, Dickinson and Company.
In October 2024, Bio-Rad Laboratories introduced its External Quality Assurance Services (EQAS) Specialty Immunoassay (SPIA) Program, covering 13 complex immunoassay analytes such as procalcitonin and IL-6. These liquid-format, ISO/IEC 17043-accredited proficiency testing kits enhance lab accuracy while reducing costs through consolidated testing.
In May 2023, the U.S. FDA granted clearance for Thermo Fisher’s B·R·A·H·M·S PlGF plus KRYPTOR and sFlt‑1 KRYPTOR immunoassays. These are the first blood-based biomarkers with breakthrough designation to assess the risk of severe preeclampsia, delivering results in under 30 minutes.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 22.24 billion |
| Market Size by 2032 | USD 38.40 billion |
| CAGR | CAGR of 7.09% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Instruments, Reagents & Consumables) • By Application (Oncology & Endocrinology, Hepatitis & Retrovirus, Cardiac Markers, Infectious Diseases, and Others) • By End user (Clinical Laboratories, Hospitals, Physicians’ Offices, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Abbott, Roche Diagnostics, DiaSorin, Danaher Corporation, QIAGEN, bioMérieux, Thermo Fisher Scientific, Quest Diagnostics, Siemens Healthineers, and Becton, Dickinson and Company |
Ans: The Immunodiagnostics market is anticipated to grow at a CAGR of 7.09% from 2025 to 2032.
Ans: The market is expected to reach USD 38.40 billion by 2032, increasing from USD 22.24 billion in 2024.
Ans: Growth of the immunodiagnostics market is driven by the rising incidence of chronic and infectious diseases, increasing availability of funds for research, and the growth in funding for research.
Ans: Regulatory complexities, high cost of advanced diagnostics, and skilled workforce gaps that challenge market expansion.
Ans: North America dominated the Immunodiagnostics market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Disease Burden and Diagnostic Demand (2024)
5.2 Immunoassay Type Distribution (2021–2032)
5.3 Reimbursement and Healthcare Spending Trends (2024)
5.4 Laboratory Capacity and Diagnostic Infrastructure (2024)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Immunodiagnostics Market Segmentation by Product
7.1 Chapter Overview
7.2 Instruments
7.2.1 Instruments Market Trends Analysis (2021-2032)
7.2.2 Instruments Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Reagents & Consumables
7.3.1 Reagents & Consumables Market Trends Analysis (2021-2032)
7.3.2 Reagents & Consumables Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Immunodiagnostics Market Segmentation By Application
8.1 Chapter Overview
8.2 Oncology & Endocrinology
8.2.1 Oncology & Endocrinology Market Trend Analysis (2021-2032)
8.2.2 Oncology & Endocrinology Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Hepatitis & Retrovirus
8.3.1 Hepatitis & Retrovirus Market Trends Analysis (2021-2032)
8.3.2 Hepatitis & Retrovirus Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Cardiac Markers
8.4.1 Cardiac Markers Market Trends Analysis (2021-2032)
8.4.2 Cardiac Markers Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Infectious Diseases
8.5.1 Infectious Diseases Market Trends Analysis (2021-2032)
8.5.2 Infectious Diseases Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Others
8.6.1 Others Market Trends Analysis (2021-2032)
8.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Immunodiagnostics Market Segmentation By End User
9.1 Chapter Overview
9.2 Clinical Laboratories
9.2.1 Clinical Laboratories Market Trends Analysis (2021-2032)
9.2.2 Clinical Laboratories Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Hospitals
9.3.1 Hospitals Market Trends Analysis (2021-2032)
9.3.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Physician’s Offices
9.4.1 Physician’s Offices Market Trends Analysis (2021-2032)
9.4.2 Physician’s Offices Market Size Estimates and Forecasts to 2032 (USD Billion)
9.5 Others
9.5.1 Others Market Trends Analysis (2021-2032)
9.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Immunodiagnostics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.2.4 North America Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.2.5 North America Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.2.6.2 USA Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.2.6.3 USA Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.2.7.2 Canada Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.2.7.3 Canada Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.2.8.2 Mexico Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.2.8.3 Mexico Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Immunodiagnostics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.4 Europe Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.5 Europe Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.6 Germany
10.3.1.6.1 Germany Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.1.6.2 Germany Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.1.6.3 Germany Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.7.2 France Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.7.3 France Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.8.2 UK Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.8.3 UK Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.9.2 Italy Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.9.3 Italy Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.10.2 Spain Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.10.3 Spain Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.12 Poland
10.3.12.1 Poland Immunodiagnostics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.12.1 Poland Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.12.3 Poland Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.12.3 Poland Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.13 Turkey
10.3.13.1 Turkey Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.13.2 Turkey Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.13.3 Turkey Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.14 Rest of Europe
10.3.14.1 Rest of Europe Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.14.2 Rest of Europe Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.14.3 Rest of Europe Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4 Asia-Pacific
10.4.1 Trends Analysis
10.4.2 Asia-Pacific Immunodiagnostics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia-Pacific Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.4 Asia-Pacific Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.5 Asia-Pacific Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.6.2 China Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.6.3 China Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.7.2 India Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.7.3 India Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.8.2 Japan Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.8.3 Japan Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.9.2 South Korea Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.9.3 South Korea Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.10.2 Singapore Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.10.3 Singapore Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.11.2 Australia Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.11.3 Australia Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.12 Rest of Asia-Pacific
10.4.12.1 Rest of Asia-Pacific Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia-Pacific Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia-Pacific Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa East Immunodiagnostics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.6.2 UAE Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.6.3 UAE Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.8.2 Qatar Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.8.3 Qatar Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9 1 South Africa Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.9 2 South Africa Immunodiagnostics Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
10.5.9 3 South Africa Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Immunodiagnostics Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.6.4 Latin America Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.6.5 Latin America Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.6.6.2 Brazil Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.6.6.3 Brazil Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.6.7.2 Argentina Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.6.7.3 Argentina Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Immunodiagnostics Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Immunodiagnostics Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Immunodiagnostics Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
12. Company Profiles
12.1 Abbott
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Roche Diagnostics
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 DiaSorin
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Danaher Corporation
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 QIAGEN
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 bioMérieux
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Thermo Fisher Scientific
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Quest Diagnostics
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Siemens Healthineers
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Becton, Dickinson and Company
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Product
Instruments
Reagents & Consumables
By Application
Oncology & Endocrinology
Hepatitis & Retrovirus
Cardiac Markers
Infectious Diseases
Others
By End user
Clinical Laboratories
Hospitals
Physician’s Offices
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players